Actinium Pharmaceuticals (ATNM) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for November 26, 2025, with advance registration required for in-person attendance.

• Voting materials include the proxy statement, proxy card, and 2024 Annual Report, available online and by request.

• Stockholders of record as of October 15, 2025, are entitled to vote; each share of common stock has one vote.

• Board recommends voting FOR Proposals 1, 2, and 3, and EVERY THREE YEARS for Proposal 4.

Voting matters and shareholder proposals

• Proposal 1: Elect Ajit Shetty and June S. Almenoff as Class III directors for a three-year term expiring at the 2028 Annual Meeting.

• Proposal 2: Ratify CBIZ CPAs P.C. as independent auditor for fiscal year ending December 31, 2025.

• Proposal 3: Approve, on a non-binding advisory basis, the compensation of named executive officers.

• Proposal 4: Approve, on a non-binding advisory basis, the frequency of future advisory votes on executive compensation, with Board recommending every three years.

• Stockholders may submit proposals for the 2026 Annual Meeting by July 8, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• Board consists of six directors divided into three classes, with staggered three-year terms.

• Five of six directors are independent under NYSE American rules.

• Chairman and CEO roles are combined, with a lead independent director to strengthen governance.

• Board committees: Audit, Compensation, and Nominating and Corporate Governance, each with independent chairs.

• Board and committees met regularly in 2024, with all directors attending at least 75% of meetings.

• Code of Business Conduct and Ethics applies to all directors, officers, and employees.

• Board diversity reviewed in 2024, resulting in the addition of Dr. June Almenoff as a director.